Biopharmaceutical products represent up to 20 percent of the total pharmaceutical market and are growing at a rate of nearly eight percent annually. To keep up with this impressive growth rate, many contract development and manufacturing organizations (CDMOs) are making strategic investments in equipment and expertise to support analytical development and structural characterization of biopharmaceuticals in more economical and efficient ways.
Unlike small molecule active pharmaceutical ingredients (APIs) that exist as a single chemical entity, biologics nearly always exist as a mixture of molecules. Different molecules can arise from numerous sources including N-terminal variants, post-translation modifications (PTMs), glycoforms, and degradation products. Due to the potentially high amount of heterogeneity in the biologic, it is critical to demonstrate control over the drug substance (DS) manufacturing process from fermentation to purification and protein re-folding. Characterization of the various molecules is the first step in demonstrating process control. High-resolution mass spectrometry is a key component in the characterization of novel biologics and biosimilars.
Thank you for your interest in learning more about biologics.
Ready to Get Started?
MORE CONTENT ON BIOLOGICS
- ALCAMI MASTER CLASS WEBINAR: Early Phase Development of Biologics
- Alcami Kickstarts Biologics Enterprise to Advance Treatments for Complex Medical Conditions
- The Top Five Most Asked Extractables and Leachables Questions Answered
- ON-DEMAND WEBINAR: Extractables & Leachables 101: The Past, Present, and Future
- White Paper: A Practical Approach to Extractables and Leachables on Manufacturing Surfaces
 McKinsey & Company 2014. Rapid growth in biopharma: challenges and opportunities.
Website visited: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/rapid-growth-in-biopharma.